A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.
Former Sen. Kyrsten Sinema told an Arizona House panel in February she's pushing for clinical trials on ibogaine as part of a "passion project." ...
The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.
Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.
Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by ...
The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...
The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...
This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.
A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target ...
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...
A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback